rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
rs1057519864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using multiple prostate cancer cell lines, we showed that catalytic Topo II inhibitors, ICRF187 and ICRF193 inhibited transcription activities of the wild-type AR, mutant ARs (F876L and W741C) and the AR-V7 splice variant.
|
26009876 |
2015 |
rs1057519864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509-treated patients with progressive disease.
|
23779130 |
2013 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
rs137852571
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.
|
12507906 |
2003 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression.
|
16636679 |
2006 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
|
19856921 |
2009 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the differential binding capacity and the favorable radioactivity pattern, (18) F-RB390 represents the portrayal of the first imaging ligand with predictive potential for mutant T877A-AR in prostate cancer for guiding therapy.Prostate 75:348-359, 2015.© 2014 Wiley Periodicals, Inc.
|
25358634 |
2015 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A.
|
18007998 |
2007 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6.
|
15790678 |
2005 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer.
|
17991730 |
2008 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.
|
25409505 |
2014 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR).
|
23813737 |
2013 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms.
|
24874833 |
2014 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we demonstrate that genistein, a soy phytoestrogen binds to both the wild and the Thr877Ala (T877A) mutant types of AR competitively with androgen, nevertheless, it exerts a pleiotropic effect on PCa cell proliferation and AR activity depending on the mutational status of the AR.
|
24167630 |
2013 |